semaglutide box Semaglutide: Diabetes Care & Weight Management Slimming down competition over weight-loss

Semaglutide is a clinically backed medication []

More fat burn

recently presented detailed Phase 2b results for berobenatide (PF3944), an investigational once-weekly and once-monthly GLP-1 receptor agonist, showing proof of concept for meaningful weight loss with low gastrointestinal side effects across obesity and type 2 diabetes populations

Patients median peak VO2the maximum amount of oxygen they could take inat study entry was 15.7, Januzzi said, which is well below the average of about 27 for a man aged 65 years or over and about 23 for a woman in the same age group

The development of oral GLP-1 medications represents an important step toward more patient-friendly metabolic care and may reshape how obesity and diabetes treatments are delivered worldwide

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D